Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.41 |
| ▸ | MMP1 known ✓ | P03956 | 1/20 | 0.37 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.37 |
| ▸ | GABRP known ✓ | O00591 | 2/20 | 0.36 |
| ▸ | GABRD known ✓ | O14764 | 2/20 | 0.36 |
| ▸ | GABRA1 known ✓ | P14867 | 2/20 | 0.36 |
| ▸ | GABRB1 known ✓ | P18505 | 2/20 | 0.36 |
| ▸ | GABRG2 known ✓ | P18507 | 2/20 | 0.36 |
| ▸ | GABRB3 known ✓ | P28472 | 2/20 | 0.36 |
| ▸ | GABRA5 known ✓ | P31644 | 2/20 | 0.36 |
| ▸ | GABRA3 known ✓ | P34903 | 2/20 | 0.36 |
| ▸ | GABRA2 known ✓ | P47869 | 2/20 | 0.36 |
| ▸ | GABRB2 known ✓ | P47870 | 2/20 | 0.36 |
| ▸ | GABRA4 known ✓ | P48169 | 2/20 | 0.36 |
| ▸ | GABRE known ✓ | P78334 | 2/20 | 0.36 |
| ▸ | GABRA6 known ✓ | Q16445 | 2/20 | 0.36 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 2/20 | 0.36 |
| ▸ | GABRG3 known ✓ | Q99928 | 2/20 | 0.36 |
| ▸ | GABRQ known ✓ | Q9UN88 | 2/20 | 0.36 |
| ▸ | ACE known ✓ | P12821 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL164110 | 0.97 | — | — | |
| SCHEMBL31198187 | 0.95 | CYP2D6 (0.48) | CYP2D6CYP2C19ALDH1A1MAPTLMNA | |
| SCHEMBL7497531 | 0.85 | CYP2D6 (0.40) | CYP2D6CYP2C19ALDH1A1MAPTLMNA | |
| SCHEMBL21309848 | 0.82 | CYP2D6 (0.46) | CYP2D6CYP2C19ALDH1A1MAPTLMNA | |
| SCHEMBL14895484 | 0.82 | CYP2D6 (0.38) | CYP2D6CYP2C19ALDH1A1MAPTLMNA | |
| SCHEMBL28418815 | 0.80 | — | — | |
| SCHEMBL287613 | 0.80 | — | — | |
| SCHEMBL287612 | 0.80 | — | — | |
| SCHEMBL7219713 | 0.80 | — | — | |
| Malonic Acid SCHEMBL28239038 | 0.79 | CYP2D6 (0.52) | CYP2D6CYP2C19ALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4638418-A1 | SYNTHESIS OF SMALL MOLECULE AGONISTS OF NEUROPTROPHIN | Oculis Operations Sàrl (CH) | 2025-10-29 | — | — | EP | disclosed |
| WO-2024133860-A1 | SYNTHESIS OF SMALL MOLECULE AGONISTS OF NEUROPTROPHIN | Oculis Operations Sàrl (CH) | 2024-06-27 | — | — | WO | disclosed |
| WO-2020253824-A1 | 18F-LABELED FLUOROPICOLINYLGLYCINE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 山西医科大学第一医院 | 2020-12-24 | — | — | WO | disclosed |
| US-20190345137-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | GALAPAGOS NV (BE) | 2019-11-14 | — | — | US | disclosed |
| US-10208020-B2 | Substituted amino triazoles useful as human chitinase inhibitors | Oncoarendi Therapeutics S.A. (PL) | 2019-02-19 | — | — | US | disclosed |
| EP-3344616-B1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | ONCOARENDI THERAPEUTICS SA (PL) | 2019-01-09 | — | — | EP | disclosed |
| US-20180258071-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | GALAPAGOS NV (BE) | 2018-09-13 | — | — | US | disclosed |
| EP-3344616-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | ONCOARENDI THERAPEUTICS S.A. (PL) | 2018-07-11 | — | — | EP | disclosed |
| US-9944624-B2 | Substituted amino triazoles useful as human chitinase inhibitors | Oncoarendi Therapeutics S.A. (PL) | 2018-04-17 | — | — | US | disclosed |
| WO-2017037670-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | OncoArendi Therapeutics Sp. z o.o. (PL) | 2017-03-09 | — | — | WO | disclosed |
| US-20040077542-A1 | Procaspase-3 activation; peptide comprising AX1 wherein X1 is V, I or L (alanine with valine, isoleucine or leucine) | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2004-04-22 | — | — | US | disclosed |
| US-6608026-B1 | Contacting pathogenic cells with AV peptoid which comprises amino acid sequence Ala-Val-Pro, is fewer than 20 residues in length, has molecular weight less than 1000, and interacts with Inhibitor of Apoptosis protein, to enhance apoptosis | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-08-19 | — | — | US | disclosed |
| WO-2002016402-A2 | APOPTOTIC COMPOUNDS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2002-02-28 | — | — | WO | disclosed |
| EP-0535155-B1 | LIBRARIES OF MODIFIED PEPTIDES WITH PROTEASE RESISTANCE | CHIRON CORP (US) | 2002-01-30 | — | — | EP | disclosed |
| US-6075121-A | HETEROPOLYMERIC PEPTOID COMPOUND CONSISTING OF 2 TO 50 N-SUBSTITUTED GLYCINES HAVING DIFFERENT ALPHA-AMINO R GROUPS; CAPABLE OF NON-NATURAL CONFIGURATIONS FOR DRUG DESIGN | CHIRON CORPORATION (US) | 2000-06-13 | — | — | US | disclosed |
| US-5965695-A | PEPTOIDS COMPRISED OF 2-50 MONOMER UNITS INCLUDING AT LEAST 2 N-SUBSTITUTED GLYCINE RESIDUES; THE PEPTOIDS ARE CONJUGATED TO A DRUG SUCH AS AZT OR TRIMETHOPRIM, FOR INCREASED BINDING AFFINITY TO A PARTICULAR BIOLOGICAL RECEPTOR | CHIRON CORPORATION (US) | 1999-10-12 | — | — | US | disclosed |
| US-5811387-A | ENZYME RESISTANT OLIGO- OR POLY-PEPTOID WHICH MAY SELECTIVELY BIND TO POLYPEPTIDE OR EFFECTOR MOLECULE; MIMETICS, PEPTOID LIBRARIES | CHIRON CORPORATION (US) | 1998-09-22 | — | — | US | disclosed |
| EP-0535155-A4 | LIBRARIES OF MODIFIED PEPTIDES WITH PROTEASE RESISTANCE | BARTLETT PAUL A (US) | 1994-08-17 | — | — | EP | disclosed |
| EP-0535155-A1 | LIBRARIES OF MODIFIED PEPTIDES WITH PROTEASE RESISTANCE | BARTLETT, Paul A. (US) | 1993-04-07 | — | — | EP | disclosed |
| WO-1991019735-A1 | LIBRARIES OF MODIFIED PEPTIDES WITH PROTEASE RESISTANCE | BARTLETT PAUL A (US) | 1991-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345137-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | CHIA, CHIT1, AADAC | PTGS2 2120/4885MMP1 1317/4885MMP8 420/4885 |
| US-10208020-B2 | Substituted amino triazoles useful as human chitinase inhibitors | CHIA, CHIT1, AADAC | PTGS2 2120/4885MMP1 1317/4885MMP8 420/4885 |
| US-20180258071-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | CHIA, CHIT1, AADAC | PTGS2 2120/4885MMP1 1317/4885MMP8 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.